Abstract
Cardiovascular risk reduction with liraglutide and semaglutide in patients with type 2 diabetes was demonstrated in the LEADER ( ClinicalTrials.gov : NCT01179048) and SUSTAIN 6 ( ClinicalTrials.gov : NCT01720446) cardiovascular outcome trials. This post hoc analysis assessed the impact of diabetes duration (P ‐interaction was not significant for all endpoints analysed).
Funding Information
  • Novo Nordisk

This publication has 13 references indexed in Scilit: